Funding (NIH)

Aronex Pharmaceuticals Awarded $1.1 Million In Grants

Published in AIDS Weekly, November 3rd, 1997

Aronex Pharmaceuticals, Inc., The Woodlands, Texas, announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded the company two Phase II Small Business Innovation Research (SBIR) grants totalling $1.1 million.

Funds are slated for the further development of Zintevir, the company's HIV integrase inhibitor currently being evaluated in a Phase I/II clinical trial.

Funds from one grant of $750,000 will be used to support the clinical trial program of Zintevir. Zintevir is currently in a Phase I/II clinical trial at New York Hospital - Cornell Medical Center. This trial is a multiple dose-escalating study designed...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-11-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry